Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Single Cell Analysis Market - Outlook to 2024: Industry Opportunities & Future Trends - ResearchAndMarkets.com

March 26, 2019

DUBLIN--(BUSINESS WIRE)--Mar 26, 2019--The “Single Cell Analysis Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com’s offering.

The Single Cell Analysis Market is expected to register a CAGR of nearly 16.5% during the forecast period, 2019-2024.

The growth of the single cell analysis market is attributed to the technological advancements in single cell analysis products, increasing investments in cancer research, and rising biotechnology and biopharmaceutical industries in recent years.

Cancer is one of the major causes of deaths across the world, and there were 8.8 million victims in 2015, accounting for nearly one in six deaths.

The disease has witnessed significant growth in the past few decades and is expected to rise rapidly over the forecast period. According to the World Health Organization (WHO), 10.9 million new cases of cancer were identified in 2002, which grew substantially over the next decade to approximately 14.1 million in 2012. An estimated 30% growth was observed over the decade. Moreover, WHO estimated the growth to increasing to 70% over the next two decades, worldwide.

Circulating tumor cells are gaining increasing clinical attention since they are likely to enable the monitoring of cancer progression and adjustment of treatment. In such cases, single-cell sequencing analysis has found its application in search of better diagnostic and prognostic biomarkers.

In recent years, multiple technologies for enrichment, isolation, as well as molecular and functional analysis of circulating tumor cells have been developed, such as single cell analysis. In 2014, the Clinical Research Infrastructure Initiative brought together several funding organizations, such as the Welcome Trust and Cancer Research UK, in partnership, led by the Medical Research Council (MRC), in order to invest over GBP 230 million for single-cell genomics for cancer studies.

In clinical diagnostics, single cell analysis is expected to standardize and automate workflows with valuable information for real-time monitoring of cancer and eventually new therapeutic strategies for the benefit of patients. This is expected to lead to more efficient and better analysis. Therefore, increasing investments in cancer research is considered as one of the major driving factors for the market over the forecast period.

Key Market Trends

Immunology Research Application is Expected to Grow with High CAGR During the Forecast Period

The cancer segment held the maximum share in 2018, owing to a high prevalence of cancer, initiatives for early detection, and increasing awareness regarding commercially available cancer diagnostics.

Immunology studies to aid in the early detection of therapeutic complications and increases the efficiency of the treatment. Furthermore, invasion of metabolic activities of single cells is increasing the adoption of its analytical tools, thus propelling the growth of immunology research segment.

North America Region Holds the Largest Market Share of Single Cell Analysis Market Currently and is Believed to Follow the Same Trend over the Forecast Period

The large share of the North American single cell analysis market is attributed to factors, such as increasing collaborations among prominent players, technological advancements, and expanding biotechnology and pharmaceutical industries. In recent years, several government initiatives have been launched that are supplementing the growth of the single cell analysis market in the region. For example, in 2015, the Precision Medicine Initiative was introduced to revolutionize the treatment of chronic diseases, including cancer.

The Asia-Pacific market is expected to witness the fastest growth during the forecast period, which is attributed to numerous government initiatives undertaken to improve healthcare infrastructure, availability of skilled professionals to operate advanced analytical instruments, and rising healthcare expenditure.

Competitive Landscape

The single cell analysis market consists of several major players. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships that help them in strengthening their market position. For instance, Illumina Inc. and Bio-Rad Laboratories Inc. entered into a strategic collaboration in 2016, to co-develop comprehensive solution for single cell genomics

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Technological Advancements in Single Cell Analysis Products

4.2.2 Increasing Investments in Cancer Research

4.2.3 Rising Biotechnology and Biopharmaceutical Industries

4.3 Market Restraints

4.3.1 High Cost of Single Cell Analysis Instruments

4.4 Porter’s Five Forces Analysis


5.1 By Cell Type

5.1.1 Human

5.1.2 Animal

5.1.3 Microbial

5.2 By Technique

5.2.1 Flow Cytometry

5.2.2 Next generation Sequencing

5.2.3 Polymerase Chain Reaction (PCR)

5.2.4 Microscopy

5.2.5 Mass Spectrometry

5.2.6 Other Techniques

5.3 By Application

5.3.1 Research Applications Cancer Research Immunology Research Neurology Research Stem Cell Research Other Research Applications

5.3.2 Medical Application Non-invasive Prenatal Diagnosis In Vitro Fertilization Circulating Tumor Cell Detection

5.4 By End User

5.4.1 Academic and Research Laboratories

5.4.2 Biotechnology and Pharmaceutical Companies

5.4.3 Hospital and Diagnostic Laboratories

5.5 Geography

5.5.1 North America

5.5.2 Europe

5.5.3 Asia-Pacific

5.5.4 Middle East & Africa

5.5.5 South America


6.1 Company Profiles

6.1.1 Agilent Technologies

6.1.2 Beckman Coulter Inc.

6.1.3 Becton, Dickinson, and Company

6.1.4 Bio-Rad Laboratories Inc.

6.1.5 Fluidigm Corporation

6.1.6 GE Healthcare

6.1.7 Illumina Inc.

6.1.8 Merck KGaA

6.1.9 Qiagen N.V.

6.1.10 Thermo Fisher Scientific Inc.


For more information about this report visit https://www.researchandmarkets.com/research/gm24qv/global_single?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190326005925/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Genomics



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/26/2019 03:19 PM/DISC: 03/26/2019 03:19 PM